FOLH1 and posterior cortical atrophy: Clinical studies have demonstrated the remarkable efficacy of 177Lu-EB-PSMA-617 in the treatment of PSMA-positive PCa [27, 28], which has led to the question whether 177Lu-EB-PSMA-617 could also achieve satisfactory therapeutic efficacy in ACC.